AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18056271
Drug: FPV-RTV (700/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPV-RTV (700/100 mg BID) with 75% reduced RFB dose (150 mg QOD)
Trial: 18056271
Drug: RFB (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RFB (300 mg QD)
Trial: 16416154
Drug: ximelagatran (2x36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran (2x36 mg daily)
Trial: 16416154
Drug: enoxaparin/warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin/warfarin
Trial: 16416154
Drug: ximelagatran (2x24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran (2x24 mg daily)
Trial: 8449013
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral mifepristone
Trial: 27663190
Drug: 1g TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g TXA intraoperative injection
Trial: 22661243
Drug: 2.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/d fish oil (GA)
Trial: 22661243
Drug: 1.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/d fish oil (GB)
Trial: 20833940
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of orally-disintegrating olanzapine
Trial: 12110113
Drug: Zolmitriptan 1
RxNorm normalized name: zolmitriptan 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 1 mg
Trial: 355661
Drug: Oral bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bethanechol chloride (25 mg)
Trial: 355661
Drug: Oral bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bethanechol chloride (50 mg)
Trial: 355661
Drug: Oral bethanechol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bethanechol chloride (100 mg)
Trial: 15114342
Drug: D-Amphetamine (AMPH)
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-Amphetamine (AMPH) 0.25 mg/kg
Trial: 8002646
Drug: Nicotinamide and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide and tetracycline (500 mg nicotinamide three times daily, 500 mg tetracycline four times daily)
Trial: 2562200
Drug: TAS (Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS (Y set with two short branches filled with electrolytic chloroxidizer solution)
Trial: 21969261
Drug: GCQ supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCQ supplement (1200 mg glucosamine hydrochloride, 60 mg chondroitin sulfate, and 45 mg quercetin glycosides per day)
Trial: 21969261
Drug: GCQ supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCQ supplement
Trial: 15241585
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) < 65 ml/min
Trial: 15241585
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance (CrCl) >= 65 ml/min
Trial: 12452237
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg x kg(‐1) and succinylcholine 1.5 mg x kg(‐1) (Group LS)
Trial: 12452237
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and succinylcholine 1.5 mg x kg(‐1) (Group PS)
Trial: 12452237
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline and rocuronium 0.6 mg x kg(‐1) (Group PR)
Trial: 10352377
Drug: Mahonia aquifolium
RxNorm normalized name: Mahonia Aquifolium Root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mahonia aquifolium ointment
Trial: 8520743
Drug: Antacids (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (30 mL every 4 h)
Trial: 8520743
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g every 4 h)
Trial: 1770194
Drug: Prophylactic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic insulin
Trial: 7060036
Drug: iv melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv melphalan (16 mg/m2 every 2 weeks for four doses, followed by a single dose every 4 weeks)
Trial: 7060036
Drug: iv melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iv melphalan (50% dose reduction)
Trial: 7060036
Drug: oral melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral melphalan (0.15 mg/kg/day for 7 days, followed by 0.05 mg/kg/day after recovery from the wbc count nadir)
Trial: 31012740
Drug: Tactile based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tactile based technology (e.g., Braille books, Braille slate and stylus)
Trial: 31012740
Drug: Visual based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual based technology (e.g., video magnifiers)
Trial: 25820754
Drug: Pegfilgrastim 60
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim 60 µg/kg/cycle
Trial: 25820754
Drug: Pegfilgrastim 100
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim 100 µg/kg/cycle
Trial: 25820754
Drug: Pegfilgrastim 120
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim 120 µg/kg/cycle
Trial: 23448344
Drug: Prasugrel reloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel reloading (20 mg)
Trial: 23448344
Drug: Clopidogrel reloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel reloading (300 mg)
Trial: 20509027
Drug: High-dose pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pegylated interferon α‐2b (peginterferon α‐2b) 6 μg/(kg week) subcutaneously for 8 weeks (induction) then 3 μg/(kg week) for 4 weeks (maintenance)
Trial: 20509027
Drug: High-dose pegylated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pegylated interferon α‐2b (peginterferon α‐2b)
Trial: 20108776
Drug: Kurarinol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kurarinol (600 mg glucose injection IV once a day for 1 month, followed by Kurarinol capsule orally three times a day for 2 months)
Trial: 20108776
Drug: Silybin Meglumine
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silybin Meglumine Tablets (used in control group, same method and dosage as treatment group)
Trial: 15197149
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and concurrent NSAIDs use
Trial: 15197149
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and aspirin taken concomitantly
Trial: 7530738
Drug: T3Ag-stimulated anti-C100-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T3Ag-stimulated anti-C100-3 antibody production
Trial: 30971276
Drug: Caffeinated gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated gum (200 mg caffeine)
Trial: 26169181
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mirabegron 50mg/day and solifenacin 10mg/day for 6 weeks
Trial: 20934856
Drug: Calcium-fortified cereal-legume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-fortified cereal-legume snack (laddoo) (500 mg of calcium carbonate)
Trial: 20934856
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate alone (500 mg)
Trial: 17121895
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches before operation
Trial: 17121895
Drug: Nitroglycerin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin treatment for 3 days before chemotherapy using DCb
Trial: 17121895
Drug: No nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nitroglycerin treatment
Trial: 17121895
Drug: Nitroglycerin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin treatment
Trial: 15578397
Drug: Intermittent rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent rifampin and pyrazinamide (RZ) therapy, given twice weekly for 2 months
Trial: 9305416
Drug: Loxiglumide (CCK-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK-A receptor antagonist)
Trial: 2691129
Drug: Perindopril with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril with beta-blocker
Trial: 4150435
Drug: Dummy tablets
RxNorm normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy tablets
Trial: 23264396
Drug: Brand-name L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand-name L-thyroxine (Synthroid)
Trial: 23264396
Drug: Generic L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic L-thyroxine (Sandoz)
Trial: 21522070
Drug: Low-dose caffeine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose caffeine (Stay Alert™ gum, 85 mg caffeine)
Trial: 16750456
Drug: Esomeprazole 20
RxNorm normalized name: esomeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 20 mg and 40 mg
Trial: 16750456
Drug: Esomeprazole (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole (both doses)
Trial: 15730653
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution for patients with middle and small burn area (Na(+) = 130 mmol/L)
Trial: 15730653
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution for patients with large burn area
Trial: 15730653
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline resuscitation for patients with large burn area (Na(+) = 174 mmol/L)
Trial: 10930892
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (RBC) based triple therapy
Trial: 10930892
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor (PPI) based triple therapy
Trial: 8965746
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-thyroxine and 150 micrograms iodine
Trial: 8965746
Drug: Mono-L-thyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mono-L-thyroxine treatment (control group B)
Trial: 24778046
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg for 6 weeks, starting at week 6 of gemcitabine therapy)
Trial: 24778046
Drug: Bevacizumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (5 mg/kg for 12 weeks, starting at week 1 of gemcitabine therapy)
Trial: 11425411
Drug: abciximab bolus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab bolus and 24 h infusion
Trial: 11425411
Drug: abciximab bolus
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: abciximab bolus and 48 h infusion
Trial: 9482293
Drug: 23-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23-valent pneumococcal capsular polysaccharide vaccine
Trial: 2536896
Drug: Propranolol (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (10, 20, 40, and 80 mg every eight hours for one day)
Trial: 2536896
Drug: Propranolol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (oral dose)
Trial: 30006792
Drug: TXT-PHE (interactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXT-PHE (interactive text conversations with Peer Health Educators, plus five‐times‐a‐day automated theory‐based messages, plus a weekly self‐monitoring text‐message assessment)
Trial: 30006792
Drug: TXT-Auto (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXT-Auto (daily automated messages and weekly self‐monitoring assessment)
Trial: 30006792
Drug: AO (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO (weekly self‐monitoring assessment only)
Trial: 28545364
Drug: Higher daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher daily light exposure
Trial: 28545364
Drug: Lower daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower daily light exposure
Trial: 25921747
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (50 mg) daily for 24 weeks
Trial: 23381973
Drug: Ruxolitinib (10-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (10-100 mg single doses and 10 mg or 25 mg every 12 hours multiple doses)
Trial: 21799145
Drug: Dialysate flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate flow rate of 800 ml/min
Trial: 21799145
Drug: Dialysate flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate flow rate of 600 ml/min
Trial: 19783805
Drug: Combined periodontal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined periodontal and triple therapy
Trial: 12931769
Drug: Preoperative oral
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative oral sedation with diazepam and local anesthetic
Trial: 9188928
Drug: Mizolastine 10
RxNorm normalized name: mizolastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 10 mg once daily
Trial: 1416574
Drug: Single 1-gram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 1-gram dose of ciprofloxacin (single-dose group; n = 40)
Trial: 1416574
Drug: 1-gram dose
RxNorm normalized name: sulbactam
DrugBank: Sulbactam (DB09324)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-gram dose of ciprofloxacin at admission and 24 hours later (2-dose group; n = 43)
Trial: 1416574
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of ciprofloxacin every 12 hours for 5 days (10-dose group; n = 35)
Trial: 3889004
Drug: None (absence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: None (absence of antibiotic prophylaxis)
Trial: 30588994
Drug: Professional oral
RxNorm normalized name: Dentek Professional Oral Care Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional oral hygiene care, toothbrushing education, and fluoride varnish application once per week for 8 weeks
Trial: 23988443
Drug: 0.05% oxymetazoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray, 100 μg dose
Trial: 23988443
Drug: Sham 'spray'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham 'spray' (untreated control)
Trial: 24032184
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Kuijiening plaster + SASP)
Trial: 24032184
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Kuijiening plaster, SASP, combined therapy)
Trial: 20216301
Drug: ART interruption
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ART interruption (drug conservation)
Trial: 14528481
Drug: Conservative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative management (expectant or medical treatment)
Trial: 7555986
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) at 40 mg/kg/day, increased to 60 and 80 mg/kg/day if seizures persisted
Trial: 1983701
Drug: Five anxiolytic
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five anxiolytic benzodiazepines taken nocte for 7 days
Trial: 7028299
Drug: Aluminium phosphate-adsorbed
RxNorm normalized name: Aluminium phosphate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aluminium phosphate-adsorbed cholera vaccine
Trial: 31290176
Drug: 20-G fine-needle
RxNorm normalized name: lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20-G fine-needle biopsy (FNB)
Trial: 28669488
Drug: Discharge Hyponatremia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge Hyponatremia (Na <135 meq/L)
Trial: 23818295
Drug: Protocol based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol based therapy (antibiotic regimens for eradication of newly identified Pseudomonas)
Trial: 23818295
Drug: Protocol based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol based therapy
Trial: 21256809
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (10 million units flat dose subcutaneously 5 days per week for 4 weeks, then 10 million units flat dose subcutaneously 3 days per week for 12 months) - Group B
Trial: 21256809
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b (10 million units flat dose subcutaneously 5 days per week for 1 month, then 10 million units flat dose subcutaneously 3 days per week for 24 months) - Group C
Trial: 14691389
Drug: Ethanol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.4 g/kg every 4 hr in 200 ml of orange juice)
Trial: 11154618
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Ginkgo biloba extract LI 1370 three times daily for 12 weeks
Trial: 9884858
Drug: remifentanil 1
RxNorm normalized name: remifentanil 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 1 microgram kg‐1 and lignocaine 1 mg kg‐1
Trial: 1111453
Drug: Intravenous clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous clindamycin phosphate
Trial: 7031847
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg trimipramine at night
Trial: 22265034
Drug: Pre-emptive ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive ibuprofen (400 mg)
Trial: 15837968
Drug: ABVD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine)
Trial: 15837968
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (subtotal nodal radiation for favorable risk or combined-modality therapy for unfavorable risk)
Trial: 15837968
Drug: Combined-modality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined-modality treatment (for unfavorable risk patients)
Trial: 12495553
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba capsules (120 mg)
Trial: 9872352
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of benfotiamine and vitamins B6 and B12
Trial: 7759675
Drug: Culturally sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally sensitive perspective to treatment outcome research
Trial: 18046976
Drug: zofenopril 30-60
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zofenopril 30-60 mg once daily
Trial: 18046976
Drug: atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 50-100 mg once daily
Trial: 11400817
Drug: 10 microg
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microg recombinant vaccine intramuscularly (IM)
Trial: 11400817
Drug: 2 microg
RxNorm normalized name: Beta 2 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 microg recombinant vaccine intradermally (ID)
Trial: 8350215
Drug: High-dose steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose steroids and Elemental diet
Trial: 16530757
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (viagra) 100 mg
Trial: 10764172
Drug: Intrathecal 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.5 mg morphine (Group IT0.5)
Trial: 10764172
Drug: Intrathecal 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal 0.1 mg morphine (Group IT0.1)